Promise already turning into fact: management shows the thing it told investors was coming is now measurably arriving, a
The model's full reasoning — Q3 2022 call → NOWe need to determine if the management's words convey a three-part pattern: prior expectation, current confirmation, and still early. The transcript is about Cue Biopharma's clinical trials, particularly CUE-101 and CUE-102. The company is developing immunotherapies. The call discusses data from trials, survival, response rates, etc. We need to see if management refers back to a previously communicated expectation about growth, and now confirms it with current data, and says it's still early. Look for phrases like "as we said", "consistent with", "we told you", etc. Also, the development should be growth-bearing, like clinical progress, patient enrollment, etc. In the transcript, management discusses the progress of CUE-101 and CUE-102. They mention that CUE-102 has started, and they had previously indicated that the platform is derisked. They also mention that they are on track with milestones. Specifically, Dan Passeri says: "With CUE-101 monotherapy expansion cohort... will have mature median overall survival data by the end of this year with a potential registration trial being defined mid-next year." That's a forward-looking statement, not a look-back. But we need a look-back to a prior expectation. For example, they might say "as we previously stated" or "consistent with our earlier guidance." Search for such phrases. In the transcript, there is a mention: "As previously and consistently stated by us, we believe CUE-101's mechanism of action..." That is a reference to prior statements, but it's about mechanism, not about a specific growth development. Also, they mention "The recent granting of Fast Track designation further underscores our confidence..." That's new, not a prior expectation. Another part: "We are excited by the preliminary data in the ongoing monotherapy and combination trial and plan to get clarity on the registrational path to approval for both lines of therapy." That's forward-looking. Look for a specific development that was promised earlier and now is being confirmed. For example, they might have said earlier that they expect to see certain response rates, and now they are seeing them. In the transcript, they compare to historical data (KEYNOTE-48) but not to their own prior expectations.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| MCD | McDonald's Corporation | Q2 2024 | 2024-07-29 | D |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| SITM | SiTime Corporation | Q2 2023 | 2023-08-02 | C+ |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| BRKL | Brookline Bancorp, Inc. | Q2 2022 | 2022-07-30 | B+ |
| UPWK | Upwork Inc. | Q2 2022 | 2022-07-27 | C+ |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ICFI | ICF International, Inc. | Q1 2017 | 2017-05-06 | B+ |
| PPG | PPG Industries, Inc. | Q1 2017 | 2017-04-20 | C |
| MDLZ | Mondelez International, Inc. | Q4 2016 | 2017-02-07 | C |
| BP | BP p.l.c. | Q4 2016 | 2017-02-07 | B+ |
| NTCT | NetScout Systems, Inc. | Q2 2017 | 2016-10-27 | D |
| F | Ford Motor Company | Q3 2016 | 2016-10-27 | B+ |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| NDSN | Nordson Corporation | Q3 2016 | 2016-08-23 | A |
| VRNS | Varonis Systems, Inc. | Q2 2016 | 2016-08-09 | B+ |
| NWSA | News Corporation | Q2 2016 | 2016-08-08 | C+ |
| CGNX | Cognex Corporation | Q2 2016 | 2016-08-01 | A |
| TRV | The Travelers Companies, Inc. | Q2 2016 | 2016-07-21 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| HD | The Home Depot, Inc. | Q4 2015 | 2016-02-23 | A |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
ICFI · Q1 2017 → YESThe question is: Does management point to a growth-bearing development that they previously told investors to expect, and now it's arriving with current activity, but still early with most contributio...YES Management explicitly references the themes from their February 2017 full-year earnings call (only two months prior), noting that the January-February pickup they had highlighted there continued through March. They then point to concrete current-period activity: ICF Olson won over $75 million in new revenue since acquisition (neither firm could have won independently), added substantial new-account wins in Q1, and saw its qualified pipeline rise significantly above year-end 2016 levels. John Wasson confirms the new projects and retainers are now lining up, with strong Q1 wins and momentum from added staff. Sudhakar states they expect mid-single-digit growth this 2017 and sequential improvement, while reiterating confidence in the medium-term outlook. The language makes clear the ramp is still early—H2 comparisons and most of the contribution lie ahead—matching the three-part pattern for this growth-bearing development. No other item in the call satisfies all three criteria as cleanly.
HOLX · Q4 2017 → YESThe question is about whether management points to a growth-bearing development they previously told investors to expect, and now it's arriving with current activity, but still early. YES The transcript shows a clear three-part pattern for international growth. Management explicitly references its prior expectation: “while we thought that international would be a double-digit grower by 2018, we've actually delivered on that promise a year earlier than anticipated.” In the just-reported Q4, they confirm the development with concrete activity 17.5% international growth (excluding Cynosure and blood), the sixth consecutive quarter of double-digit growth for molecular internationally, and Panther shipments exceeding prior-year levels. They also state it is still early with most contribution ahead: “we've actually delivered on that promise a year earlier,” and they hope investors remember this 2017 success story as they evaluate Cynosure 2.
PTC · Q3 2017 → YESThe question is about whether management points to a growth-bearing development they previously told investors to expect, and now it's arriving with current activity, but still early. YES Management explicitly references its prior long-term growth ambition for IoT (30-40% bookings growth, consistent with the faster-growing IoT market) as part of its double-digit overall plan, which it had communicated as the target to achieve sustainable growth. In the current quarter, it confirms this is materializing with 40%+ of IoT bookings from customer expansions, six-figure deals growing sequentially and year-over-year, and specific closed expansions with leading food/beverage, aerospace/defense, and medical device companies, plus strong contribution from these. It further conveys the development remains early by noting customers are "generally still in the early days of their IoT journeys" with "adoption is gaining momentum" and "further stages" (e.g.